Sector News

Good thing Bayer's in Germany, CEO says. U.S. business culture is too impatient

November 4, 2015
Life sciences

Bayer CEO Marijn Dekkers–at one time a wannabe professional tennis player–knows what it is to push it to the limit. But he also knows that too much pushing can take its toll.

“I’m very aware of the strain and stresses on my body, both physically and mentally, and put a lot of measures in place to manage that,” he recently told the Financial Times of the CEO’s role. “I know from my tennis days what it is to manage your energy. On the day of a match you need to peak at, say, 2 p.m., not 5 p.m.”

And too much pushing can take its toll on a company, too, he pointed out–especially in a big company with deep historical roots, like Bayer.

“You can stretch it, but when does it snap? [If] you force people along at a faster pace than they are capable of, you end up out there on your own and no one knows what you are talking about,” he said.

That’s one good thing about Germany’s business culture, he told the paper–especially if you’re running a company “with a very long timeframe.” In the U.S. “pressure comes too quickly–particularly when things go awry.

“People start knocking on your door saying, ‘Why don’t you sell this’ or ‘I want to be on your board as an activist’,” he pointed out.

That’s not to say Dekkers hasn’t shaken things up at Bayer since taking the helm. He’s transformed the company from a chemicals conglomerate into one more focused on life sciences, most recently cementing that identity by floating Bayer’s plastics unit, Covestro, in an IPO.

Now, though, he’s ready to slow things back down–personally, that is. The 58-year-old skipper requested his contract be extended only until the end of next year, he announced last summer, and at that point, he plans to walk away from C-suite life for good.

With his children preparing to go off to college in the U.S., “I need flexibility to spend more time in the U.S. and not have to be at a meeting here on Monday morning that I cannot miss,” he told the FT.

In the meantime, though, its hot-selling products are keeping up their speedy clips. Eye med Eylea, for one, posted a strong numbers in Q3, with sales jumping 69% year over year. That performance prompted Bayer to increase its growth guidance for the drug to 50% for 2015.

By Carly Helfand

Source: Fierce Pharma

comments closed

Related News

December 5, 2021

Catherine Mazzacco is leaving the position as President and CEO of LEO Pharma

Life sciences

After more than two years of leading LEO Pharma through a major transformation and a change of capital structure in a volatile environment during the global pandemic, the Board of Directors of LEO Pharma and President and CEO Catherine Mazzacco have jointly agreed that she will resign from her current role and leave the company on November 30, 2021.

December 5, 2021

Lonza and Bioqube Ventures to scale biologics and small molecules

Life sciences

Lonza and Bioqube Ventures, a European venture capital firm with a dual investment model including venture creation, have partnered to develop and manufacture biologics and small molecules. This is a five-year services agreement in which Lonza will provide advice and services to Bioqube Ventures’ portfolio companies.

December 5, 2021

UCB and Chiesi enter global license agreement for zampilimab a novel monoclonal antibody for fibrotic lung diseases

Life sciences

UCB has granted to Chiesi global exclusive rights to develop, manufacture and commercialize zampilimab, a monoclonal antibody targeting transglutaminase 2 (TG2), an enzyme associated in fibrotic diseases. UCB will receive upfront payment, future milestone payments and net sales royalties.

Send this to a friend